Novartis Investigative Site

Bratislava, Slovakia 85107

2 studies enrolling now · 11 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Heart Failure With Reduced Ejection Fraction, Hypertension, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Systolic Hypertension, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Recruiting now
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age — Completed
• An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension — Completed
• Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age — Completed
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension — Completed